Dextrose
drugOn this page
Also known as Anhydrous dextroseAnhydrous glucoseCapdClintecD-glucoseanhydrousD5WDextro energyDextrogelDextrose anhydrousDextrose component of navstelDextrose solutionunspecifiedunspecified formGambrosolGlucoseGlucose anhydrousGlucose injectionalpha-d-
Summary
Dextrose (CHEMBL1222250) is an approved small molecule (ATC B05CX01); indicated across 69 conditions including varicose disease and myocardial infarction.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: B05CX01 (+3 more)
- Indications: 69 conditions
- Clinical trials: 464
- Chemistry: 180.16 Da · C6H12O6
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1222250 |
| Name | Dextrose |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5793 |
| ChEBI | CHEBI:4167 |
| ATC | B05CX01, C05BB56, V06DC01, V04CA02 |
| Molecular formula | C6H12O6 |
| Molecular weight | 180.16 |
| InChIKey | WQZGKKKJIJFFOK-GASJEMHNSA-N |
SMILES: C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)O
IUPAC name: (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
ChEBI definition: A glucopyranose having D-configuration.
Other ChEBI roles (chemical / environmental): human metabolite, Saccharomyces cerevisiae metabolite, Escherichia coli metabolite, mouse metabolite.
Also known as: Anhydrous dextrose, Anhydrous glucose, Capd, Clintec, D-glucose, anhydrous, D5W, Dextro energy, Dextrogel, Dextrose, Dextrose anhydrous, Dextrose component of navstel
Patent coverage: 850,563 distinct patent families (2,121,542 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
69 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| varicose disease | 4 | MONDO:0008638 | HP:0002619 |
| myocardial infarction | 3 | MONDO:0005068 | EFO:0000612 |
| heart failure | 3 | MONDO:0005252 | EFO:0003144 |
| liver disorder | 3 | MONDO:0005154 | EFO:0001421 |
| hepatocellular carcinoma | 3 | MONDO:0007256 | EFO:0000182 |
| congestive heart failure | 3 | MONDO:0005009 | EFO:0000373 |
| epilepsy | 3 | MONDO:0005027 | EFO:0000474 |
| toxic shock syndrome | 3 | MONDO:0001881 | EFO:0006834 |
| intermediate coronary syndrome | 3 | MONDO:0006805 | EFO:1000985 |
| neutropenia | 3 | MONDO:0001475 | MONDO:0001475 |
| breast neoplasm | 3 | MONDO:0021100 | EFO:0003869 |
| ileus | 3 | MONDO:0004567 | MONDO:0004567 |
| epicondylitis | 3 | MONDO:0001875 | EFO:1001896 |
| multiple sclerosis | 3 | MONDO:0005301 | MONDO:0005301 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| polycystic ovary syndrome | 3 | MONDO:0008487 | EFO:0000660 |
| influenza | 3 | MONDO:0005812 | EFO:0007328 |
| coronary artery disorder | 3 | MONDO:0005010 | EFO:0001645 |
| carpal tunnel syndrome | 3 | MONDO:0007275 | EFO:0004143 |
| chronic kidney disease | 3 | MONDO:0005300 | EFO:0009909 |
| marginal zone lymphoma | 3 | MONDO:0017604 | EFO:1000630 |
| hearing loss disorder | 2 | MONDO:0005365 | EFO:0004238 |
| diabetes mellitus | 2 | MONDO:0005015 | EFO:0000400 |
| obesity disorder | 2 | MONDO:0011122 | EFO:0001073 |
| gastroparesis | 2 | MONDO:0006769 | EFO:1000948 |
| metabolic disease | 2 | MONDO:0005066 | EFO:0000589 |
| bacterial vaginosis | 2 | MONDO:0005316 | EFO:0003932 |
| hypospadias | 2 | MONDO:0005345 | EFO:0004209 |
| common cold | 2 | MONDO:0005709 | EFO:0007214 |
| disease of the tendon | 2 | MONDO:0100010 | EFO:1001434 |
| temporomandibular joint disorder | 2 | MONDO:0005473 | EFO:0005279 |
| amyotrophic lateral sclerosis | 2 | MONDO:0004976 | MONDO:0004976 |
| hyperlipidemia | 2 | MONDO:0021187 | MONDO:0021187 |
| porphyria | 2 | MONDO:0037939 | MONDO:0037939 |
| HIV infectious disease | 2 | MONDO:0005109 | EFO:0000764 |
| bone fracture | 2 | MONDO:0005315 | EFO:0003931 |
| osteoarthritis, knee | 2 | MONDO:0005416 | EFO:0004616 |
| schizoaffective disorder | 2 | MONDO:0005487 | EFO:0005411 |
| ependymoma | 2 | MONDO:0016698 | EFO:1000028 |
| craniopharyngioma | 2 | MONDO:0018907 | EFO:1000209 |
| hypoglycemia | 1 | MONDO:0004946 | HP:0001943 |
| pneumonia | 1 | MONDO:0005249 | EFO:0003106 |
| fungal infectious disease | 1 | MONDO:0002041 | MONDO:0002041 |
| brain injury | 1 | MONDO:0043510 | MONDO:0043510 |
| respiratory failure | 1 | MONDO:0021113 | EFO:0009686 |
| gastroschisis | 1 | MONDO:0009264 | EFO:1000949 |
| type 1 diabetes mellitus | 1 | MONDO:0005147 | MONDO:0005147 |
| type 2 diabetes mellitus | 1 | MONDO:0005148 | MONDO:0005148 |
| metabolic syndrome X | 1 | MONDO:0011565 | EFO:0000195 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| spinal cord injury | 1 | MONDO:0043797 | MONDO:0043797 |
| hypertensive disorder | 0 | MONDO:0005044 | EFO:0000537 |
| cystic fibrosis | 0 | MONDO:0009061 | MONDO:0009061 |
16 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 464.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 308 |
| PHASE4 | 45 |
| PHASE1 | 31 |
| PHASE2 | 25 |
| PHASE3 | 23 |
| EARLY_PHASE1 | 17 |
| PHASE1/PHASE2 | 8 |
| PHASE2/PHASE3 | 7 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04082533 | PHASE4 | ACTIVE_NOT_RECRUITING | Intravenous (IV) Hydrocortisone for TKA (Total Knee Arthroplasty) |
| NCT05264727 | PHASE4 | ACTIVE_NOT_RECRUITING | Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion |
| NCT06726980 | PHASE4 | NOT_YET_RECRUITING | Effects of Dextrose Versus Saline Infusion on Intrathecal Morphine-Induced Postoperative Nausea and Vomiting During Gynecological Abdominal Surgeries: Randomized Controlled Double-blind Study |
| NCT06936709 | PHASE4 | NOT_YET_RECRUITING | Perioperative Colchicine for TKA |
| NCT07189091 | PHASE4 | RECRUITING | CReep and Maintenance flUid Sodium Chloride ADministration rEduction in cRitically Ill adultS |
| NCT07283874 | PHASE4 | NOT_YET_RECRUITING | Does it Matter the Volume of Injectate on the Outcome of Ultrasound-guided Perineural Injection for Carpal Tunnel Syndrome |
| NCT07382596 | PHASE4 | RECRUITING | Cervical Plexus Hydrodissection With D5W Versus NS for Treatment-Resistant PTSD |
| NCT07494084 | PHASE4 | NOT_YET_RECRUITING | Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance |
| NCT00572767 | PHASE4 | TERMINATED | Evaluation of the Effect of Dextro-Amphetamin Added to Physiotherapy in Patients After Stroke |
| NCT00709839 | PHASE4 | COMPLETED | Rapid Effects of Hydrocortisone on Glucose-induced Insulin Secretion in Healthy Humans |
| NCT00878878 | PHASE4 | COMPLETED | Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). |
| NCT01253889 | PHASE4 | COMPLETED | Sweetheart Study: Oral Glucose for Reducing Stress During Echocardiographic Assessment in Infants in the NICU |
| NCT01326611 | PHASE4 | COMPLETED | Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants |
| NCT01387477 | PHASE4 | WITHDRAWN | Lactate to Treat Hypoglycemia |
| NCT01818583 | PHASE4 | COMPLETED | Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter |
| NCT02054325 | PHASE4 | COMPLETED | Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins |
| NCT02102243 | PHASE4 | WITHDRAWN | Neural Mechanism of Aldosterone-induced Insulin Resistance |
| NCT02441842 | PHASE4 | COMPLETED | Evaluation of Periop Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preop Hypertension |
| NCT02590081 | PHASE4 | UNKNOWN | Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients |
| NCT02657252 | PHASE4 | COMPLETED | Polidocanol Versus Glucose Treatment of Telangiectasia Trial |
| NCT02765204 | PHASE4 | COMPLETED | A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes |
| NCT02980250 | PHASE4 | COMPLETED | Multi-Center Study of Different Doses Domperidone in Feeding Intolerance |
| NCT02984098 | PHASE4 | COMPLETED | 40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose |
| NCT03126084 | PHASE4 | COMPLETED | Postoperative Effects of TAP Block Versus QLB Type 2 Block |
| NCT03238183 | PHASE4 | UNKNOWN | Effects of Dextrose on Knee Osteoarthritis |
| NCT03587441 | PHASE4 | COMPLETED | Intrathecal Neostigmine for Prevention of PDPH |
| NCT03589495 | PHASE4 | COMPLETED | Safety and Efficacy of Adding Intravenous N-acetyl Cysteine in Colon Surgeries |
| NCT03666546 | PHASE4 | COMPLETED | Blood Glucose Response After Oral Intake of Lactulose in Mildly Constipated Patients With Diabetes Mellitus Type 2 |
| NCT03729271 | PHASE4 | COMPLETED | Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea |
| NCT03998709 | PHASE4 | WITHDRAWN | Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion |
| NCT04062838 | PHASE4 | WITHDRAWN | Prolotherapy for the Treatment of Partial Rotator Cuff Tears |
| NCT04106882 | PHASE4 | UNKNOWN | Dynamic Connectivity Under Metabolic Constraints |
| NCT04245774 | PHASE4 | COMPLETED | Comparing the Effects of Levobupivacaine and Bupivacaine in Saddle Spinal Anesthesia |
| NCT04680936 | PHASE4 | COMPLETED | Low and High Dose Dextrose Prolotherapy in the Treatment of Lateral Epicondylitis |
| NCT04840095 | PHASE4 | UNKNOWN | Dynamic Connectivity Under Metabolic Constraints |
| NCT04949139 | PHASE4 | COMPLETED | Efficacy and Safety of Rapid Intermittent Correction Compared With Slow Continuous Correction in Patients With Severe Hypernatremia |
| NCT05131269 | PHASE4 | COMPLETED | Prolotherapy Intervention in Patient With Frozen Shoulder |
| NCT05289323 | PHASE4 | COMPLETED | Effect of Intrathecal Neostigmine on Post-dural Puncture Headache. |
| NCT05496764 | PHASE4 | UNKNOWN | Local Injection of Steroid VS.Glucose 5% in Carpal Tunnel Syndrome |
| NCT05918146 | PHASE4 | UNKNOWN | Dextrose Therapy on Physical Therapy in Subdeltoid Bursitis |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 5 variant annotation(s) for this drug (gene-keyed; see PharmGKB).
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: varicose disease, myocardial infarction, heart failure, liver disorder, hepatocellular carcinoma, congestive heart failure, epilepsy, toxic shock syndrome, intermediate coronary syndrome, neutropenia, breast neoplasm, ileus, epicondylitis, multiple sclerosis, severe acute respiratory syndrome, polycystic ovary syndrome, influenza, coronary artery disorder, carpal tunnel syndrome, chronic kidney disease, marginal zone lymphoma